CompletedNCT00088465
Long-term treatment with injectable olanzapine for schizophrenia
About this title
Read the official source — NCT00088465Medication studyAges 18–76Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 76 years.
- Listed locations
- Orange and 91 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 931
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 76 Years
- Official registry ID
- NCT00088465
- Official title
Show the full official title
An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Orange, United States · Pasadena, United States · San Diego, United States
91 more locations
- Santa Ana, United States
- Washington D.C., United States
- Bradenton, United States
- Honolulu, United States
- Chicago, United States
- Indianapolis, United States
- Lake Charles, United States
- St Louis, United States
- Las Vegas, United States
- Reno, United States
- Albuquerque, United States
- Cedarhurst, United States
- New York, United States
- Rochester, United States
- Chagrin Falls, United States
- Chardon, United States
- Houston, United States
- Kirkland, United States
- Buenos Aires, Argentina
- Lanús Este, Argentina
- Mendoza, Argentina
- Herston, Australia
- Glenside, Australia
- Dandenong, Australia
- Vienna, Austria
- Diest, Belgium
- Liège, Belgium
- Aparecida de Goiânia, Brazil
- Rio de Janeiro, Brazil
- Salvador, Brazil
- Zagreb, Croatia
- Prague, Czechia
- Bayonne, France
- Bourg-en-Bresse, France
- Dijon, France
- Dole, France
- Fontaine, France
- La Roche-sur-Foron, France
- La Seyne-sur-Mer, France
- Limoges, France
- Narbonne, France
- Paris, France
- Saint-Cyr-au-Mont-d'Or, France
- Strasbourg, France
- Suresnes, France
- Bad Saarow, Germany
- Berlin, Germany
- Halle, Germany
- Hamburg, Germany
- Mainz, Germany
- München, Germany
- Budapest, Hungary
- Beer Yaacov, Israel
- Hod HaSharon, Israel
- Lev Hasharon, Israel
- Florence, Italy
- Savigliano, Italy
- Torino, Italy
- Guadalajara, Mexico
- Mexico City, Mexico
- Monterrey, Mexico
- Enschede, Netherlands
- The Hague, Netherlands
- Gdynia, Poland
- Torun, Poland
- Braga, Portugal
- Coimbra, Portugal
- Lisbon, Portugal
- Porto, Portugal
- Mayagüez, Puerto Rico
- Ponce, Puerto Rico
- Rio Piedras, Puerto Rico
- San Juan, Puerto Rico
- Bucharest, Romania
- Craiova, Romania
- Iași, Romania
- Moscow, Russia
- Saint Petersburg, Russia
- Bratislava, Slovakia
- George, South Africa
- Randburg, South Africa
- Barcelona, Spain
- Burgos, Spain
- Málaga, Spain
- Seville, Spain
- Falköping, Sweden
- Stockholm, Sweden
- Taipei, Taiwan
- Taoyuan, Taiwan
- Czechia
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Intramuscular olanzapine depot.
Who was this study for?
Listed age limits: 18 years to 76 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia